The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adverse events of patients treated with antibody-drug conjugates in phase 1 clinical trials at the Royal Marsden Drug Development Unit from 2014 to 2024.
 
Harold Nathan Tan
No Relationships to Disclose
 
Marta Ascanio Morcillo
No Relationships to Disclose
 
Johann S. De Bono
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; ImCheck therapeutics; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; Pfizer; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics (Inst); Boehringer Ingelheim (Inst); CellCentric; Crescendo Biologics (Inst); Daiichi Sankyo; Dark Blue Therapeutics (Inst); Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon therapeutics; ImCheck therapeutics; Immunic Therapeutics; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; MetaCurUm; Myricx Pharma; Novartis; Nurix (Inst); Oncternal Therapeutics; Orion; Pfizer (Inst); Qiagen; Sanofi Aventis GmbH (Inst); Sierra Oncology; Taiho Oncology; Takeda (Inst); Tango Therapeutics (Inst)
Speakers' Bureau - AstraZeneca
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); CellCentric (Inst); Crescendo Biologics (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Harpoon (Inst); Immunic Therapeutics (Inst); Janssen (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MetaCurUm (Inst); Myricx (Inst); Nurix (Inst); Oncternal Therapeutics (Inst); Orion (Inst); Pfizer (Inst); Sanofi Aventis GmbH (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; Bayer; Cellcentric; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; Halda Therapeutics; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi
 
Juanita Suzanne Lopez
Consulting or Advisory Role - Basilea; CureTeq; Ellipses Pharma; Genmab; GlaxoSmithKline; Novartis; Pierre Fabre; Roche/Genentech
Research Funding - Astex Pharmaceuticals (Inst); Basilea (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Basilea; Roche/Genentech
 
Anna Rachel Minchom
Honoraria - GlaxoSmithKline; Janssen; Merck; Seagen
Consulting or Advisory Role - Faron Pharmaceuticals; GlaxoSmithKline; Janssen Oncology; MSD
Research Funding - Astex Pharmaceuticals (Inst); Merck (Inst); MSD Oncology (Inst)
Travel, Accommodations, Expenses - Janssen Oncology
 
Adam Sharp
Honoraria - Astellas Pharma; Merck Sharp & Dohme
Consulting or Advisory Role - CHARM Therapeutics; D. E. Shaw Research; DROIA; Ellipses Pharma
Patents, Royalties, Other Intellectual Property - Adam Sharp is an employee of the ICR, which has a commercial interest in abiraterone, PARP inhibition in DNA repair defective cancers, and PI3K/AKT pathway inhibitors (no personal income) (Inst)
Travel, Accommodations, Expenses - Nurix; Roche/Genentech; Sanofi
 
Alec Paschalis
Patents, Royalties, Other Intellectual Property - Named on patent held by the Institute of Cancer Research (ICR) together with Cancer Research UK identifying JMJD6 as a therapeutic target in advanced prostate cancer. (Inst)
 
Udai Banerji
Employment - Institute of Cancer Research
Consulting or Advisory Role - Carrick Therapeutics; Ellipses Pharma; PEGASCY; PharmEnable
Research Funding - Avacta Life Sciences (Inst); BTG (Inst); Carrick Therapeutics (Inst); Chugai Pharma (Inst); Verastem (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Bayer; Sierra Oncology